GlassScriptPhysician profile
Joseph E Fouche
NPI 1609043249
$5,174.95
in general payments reported to CMS, 2019-2025
55 companies · $1,888 in 2025
The $1,888 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.56 · 2020: $20.11 · 2021: $169 · 2022: $280 · 2023: $972 · 2024: $1,830 · 2025: $1,888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,648 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,647.73 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $577.31 | 2019-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $499.43 | 2024-2025 | Opdivo, Krazati, Opdualag |
| Janssen Biotech, INC. | $367.60 | 2021-2025 | Darzalex, Balversa, Erleada |
| Daiichi Sankyo INC. | $333.58 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $302.34 | 2021-2025 | |
| Pfizer INC. | $297.38 | 2020-2025 | |
| Abbvie INC. | $169.70 | 2023-2025 | |
| Astellas Pharma US INC | $150.49 | 2023-2025 | Xtandi, Padcev, Vyloy |
| Astrazeneca Pharmaceuticals LP | $145.69 | 2023-2025 | Imfinzi, Enhertu |
| Glaxosmithkline, LLC. | $139.65 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Exelixis INC. | $125.16 | 2022-2025 | Cabometyx |
| Sanofi-Aventis U.S. LLC | $125.00 | 2025 | |
| Incyte Corporation | $124.96 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $109.14 | 2021-2025 | |
| Genentech USA, INC. | $101.32 | 2022-2025 | Venclexta, Polivy, Tecentriq |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $99.54 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $93.44 | 2021-2023 | Imbruvica |
| Genmab U.S., INC. | $91.05 | 2023-2025 | Epkinly |
| Lilly USA, LLC | $83.83 | 2023-2025 | Verzenio, Jaypirca |
| Beigene USA, INC. | $81.79 | 2022-2025 | Brukinsa, Tevimbra |
| Celgene Corporation | $81.23 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Seagen INC. | $80.78 | 2022-2023 | Adcetris, Padcev |
| Kyowa Kirin, INC. | $59.44 | 2024-2025 | Poteligeo |
| Takeda Pharmaceuticals U.S.A., INC. | $59.38 | 2022-2025 | Ninlaro |
| Gilead Sciences, INC. | $56.71 | 2021-2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $49.68 | 2022-2025 | |
| Springworks Therapeutics, INC. | $49.14 | 2024-2025 | Ogsiveo, Gomekli |
| Tempus Ai, INC | $46.57 | 2024-2025 | Xt Cdx |
| Jazz Pharmaceuticals INC. | $45.04 | 2023-2024 | |
| Legend Biotech USA INC. | $43.07 | 2024-2025 | Carvykti |
| Mirati Therapeutics, INC. | $42.00 | 2023 | Krazati |
| Emd Serono, INC. | $40.23 | 2023-2025 | Bavencio |
| Stemline Therapeutics INC. | $38.86 | 2023-2025 | Orserdu |
| Geron Corporation | $38.55 | 2024-2025 | Rytelo |
| Tersera Therapeutics LLC | $33.14 | 2023-2025 | Zoladex |
| Amgen INC. | $31.37 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $30.08 | 2023 | Libtayo |
| Sobi, INC | $24.23 | 2025 | |
| Caris Mpi, INC. | $23.53 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $22.77 | 2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.44 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.25 | 2024 | Ultomiris |
| Array Biopharma INC | $19.66 | 2025 | Braftovi, Mektovi, Tukysa |
| Azurity Pharmaceuticals, INC. | $19.19 | 2024 | Triptodur |
| Genzyme Corporation | $19.11 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.58 | 2023 | |
| Deciphera Pharmaceuticals INC. | $18.06 | 2023 | Qinlock |
| Recordati_rare_diseases_inc. | $17.17 | 2025 | Sylvant |
| Morphosys, US INC. | $16.99 | 2023 | Monjuvi |
| Puma Biotechnology, INC. | $16.86 | 2025 | |
| Taiho Oncology, INC. | $16.23 | 2023 | |
| Agios Pharmaceuticals, INC. | $15.30 | 2024 | |
| Novocure INC. | $14.64 | 2025 | Optune Lua (Novottf-200t) |
| Kite Pharma, INC. | $13.76 | 2023 | Yescarta |
| Janssen Pharmaceuticals, INC | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Fouche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.